Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 17.75 0.85% 0.15
STML closed up 0.85 percent on Friday, February 23, 2018, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
3 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical STML trend table...

Date Alert Name Type % Chg
Feb 23 New 52 Week Closing High Bullish 0.00%
Feb 23 Stochastic Reached Overbought Strength 0.00%
Feb 23 Inside Day Range Contraction 0.00%
Feb 23 BB Squeeze Ended Range Expansion 0.00%
Feb 23 Wide Bands Range Expansion 0.00%
Feb 23 Above Upper BB Strength 0.00%
Feb 23 Overbought Stochastic Strength 0.00%
Feb 23 Up 3 Days in a Row Strength 0.00%
Feb 23 Upper Bollinger Band Touch Strength 0.00%
Feb 22 MACD Bullish Signal Line Cross Bullish 0.85%

Older signals for STML ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.0
52 Week Low 6.85
Average Volume 298,687
200-Day Moving Average 11.5353
50-Day Moving Average 15.1273
20-Day Moving Average 16.1548
10-Day Moving Average 16.192
Average True Range 1.0036
ADX 20.73
+DI 27.19
-DI 13.74
Chandelier Exit (Long, 3 ATRs ) 14.9892
Chandelier Exit (Short, 3 ATRs ) 17.3108
Upper Bollinger Band 17.4338
Lower Bollinger Band 14.8758
Percent B (%b) 1.12
BandWidth 15.834303
MACD Line 0.5321
MACD Signal Line 0.3855
MACD Histogram 0.1467
Fundamentals Value
Market Cap 416.32 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -7.19
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.73
Resistance 3 (R3) 18.64 18.22 18.57
Resistance 2 (R2) 18.22 17.97 18.27 18.51
Resistance 1 (R1) 17.99 17.82 18.11 18.08 18.46
Pivot Point 17.57 17.57 17.63 17.61 17.57
Support 1 (S1) 17.33 17.32 17.45 17.42 17.04
Support 2 (S2) 16.91 17.16 16.96 16.99
Support 3 (S3) 16.68 16.91 16.93
Support 4 (S4) 16.77